Personalized neoantigen tumor vaccine(Ruijin Hospital)

The main purpose of this study is to observe and evaluate the safety and tolerance of XP-004 personalized mRNA vaccine encoding tumor neoantigen combined with PD-1 inhibitor for adjuvant treatment of patients who cannot tolerate chemotherapy after radical resection of pancreatic cancer.
The secondary objective was to observe the initial efficacy of adjuvant therapy with XP-004 personalized mRNA vaccine combined with PD-1 inhibitor in patients with pancreatic cancer after radical surgery by the indicators of XP-004 personalized mRNA vaccine induced activstion of Antigen specific CD4 and CD8 T cells, Recurrence free survival (RFS), and Overall Survival (OS).